Skip to main content
Psomagen, Inc. logo

Psomagen, Inc. — Investor Relations & Filings

Ticker · 950200 ISIN · KR8840150005 KO Professional, scientific and technical activities
Open in API
Filings indexed 180 across all filing types
Latest filing 2024-11-26 Major Shareholding Noti…
Country US United States of America
Listing KO 950200

About Psomagen, Inc.

https://www.psomagen.com/

Psomagen, Inc. is a contract laboratory service provider specializing in multiomics and data analysis solutions for scientists and clinicians. Operating from CLIA-certified and CAP-accredited facilities, the company offers a comprehensive suite of services to the academic, clinical, and life sciences research communities. Its core offerings encompass genomics, epigenomics, proteomics, transcriptomics, and metagenomics. Psomagen utilizes a range of sequencing technologies, including Sanger sequencing, Next-Generation Sequencing (NGS), and third-generation sequencing. The company also provides specialized solutions such as spatial biology analysis, cell line authentication via STR profiling, and advanced bioinformatics support to analyze complex biological data.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등거래계획보고서
Major Shareholding Notification Classification · 100% confidence The document is a formal 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주특정증권등거래계획보고서) filed by Macrogen regarding its stake in Somagen. This document details a planned acquisition of shares by a major shareholder, which falls under the category of insider trading/shareholding activity reporting. In the provided taxonomy, 'Director's Dealing' (DIRS) is the most appropriate category for reports concerning share transactions or trading plans by directors and major shareholders.
2024-11-26 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Psomagen, Inc.' (주식회사 소마젠) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, management discussion, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) and a subsequent amendment (정정신고) to that contract. It details the change in contract value for a supply agreement with ModernaTX, Inc. Since this is a specific regulatory disclosure of a material business event (contract amendment) that does not fit into categories like earnings, dividends, or board changes, it falls under the general regulatory filing category.
2024-09-10 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between Somagen and the National Institutes of Health (NIH). It details the contract value, duration, and nature of the services provided. Since this is a specific material event disclosure regarding a business contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2024-08-21 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Psomagen, Inc.' covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial statements, management discussion, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between the company (Somagen) and ModernaTX, Inc. It details the contract value, duration, and nature of the services provided. Since this is a specific material event disclosure regarding a business contract that does not fit into the other specialized categories like M&A or share issues, it falls under the general regulatory filing category.
2024-07-02 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.